Abstract: Disclosed is a compound having a structure in formula I. The compound of the present invention has good enzyme inhibitory activity against EGFR mutants (L858R/T790M/C797S, del19/T790M/C797S, del19/C797S, L858R/C797S), a weak inhibitory effect on wild-type EGFR, and good selectivity. The compound has significant inhibitory activity against the proliferation of EGFR mutant cells, and has potential application value in the treatment of diseases related to cell proliferation. The compound of the present invention has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential pharmaceutical compound.

Abstract: A biomimetic ice growth inhibition material is prepared. by constructing a library for structures of compound molecules, with the compound molecules comprising a hydrophilic group and an ice-philic group, by evaluating the spreading performance of each compound molecule at an ice-water interface by adopting molecular dynamics simulation (MD simulation), and by screening the compound molecules with the desired affinities for ice and water. The present invention firstly provides the mechanism of the affinities of the ice growth inhibition material for ice and water, introduces MD simulation into the molecular structure design of the ice growth inhibition material, evaluates the affinities of the designed ice growth inhibition material for ice and water through MD simulation, predicts the ice growth inhibition performance of the ice growth inhibition material, and can realize the optimization of the structure.

Abstract: A thawing solution has 0.1-50 g of a biomimetic material for controlling ice, 0-1.0 mol L?1 of a water-soluble sugar, and balance of a buffer solution. The biomimetic material for controlling ice is a material for controlling ice having an ice-philic group and a hydrophilic group. The hydrophilic group is a functional group that can form a non-covalent interaction with water molecules, and the ice-philic group is a functional group that can form a non-covalent interaction with ice. Using the thawing solution and the thawing reagent prepared from the biomimetic material for controlling ice, which material has ice-philic and hydrophilic properties, the growth and recrystallization of ice crystals can be effectively controlled, and damage to cells or tissue caused by uncontrolled growth of the ice crystals during recovery can be significantly ameliorated.

Abstract: A cryopreservation solution contains 0.01-50.0 g of bionic ice control materials, 5.0-30 mL of polyols, 1-30 g of water-soluble sugar, and 0-30 mL of serum, and a buffer in every 100 mL of the cryopreservation solution. It does not contain DMSO. When being used for the cryopreservation of mouse oocytes and embryos, the solution may achieve the same or an even higher cell and tissue survival rate and functional expression stability as or than a commercial cryopreservation solution (containing 15% DMSO), and has high preservation efficiency. The cryopreservation solution without DMSO or serum reduces parasitic biological contaminants in the commercial cryopreservation solution containing serum currently used in clinical practice.

Abstract: A serum-free cryopreservation solution contains a biomimetic ice control material, a polyol, a water-soluble sugar, and a buffer solution margin. The bionic ice control material can be polyvinyl alcohol or an amino acid compound. The cryopreservation liquid of the present invention uses the bionic ice control material as the main component, does not contain serum, has low toxicity, and can achieve a cell survival rate that is the same as, or higher than, existing cryopreservation solutions.

Abstract: The invention generally relates to a novel method and related compositions for detecting and analyzing cancer. More particularly, the invention relates to unique methods, compositions and assays useful for diagnosing and measuring the presence and/or risk of ovarian cancer involving the utilization of various generic and epigenetic biomarkers.